The top ten clues to understand the origin of chronic lymphocytic leukemia (CLL)

Journal of Autoimmunity

Volumn 56, Issue , 2015, Pages 81-86

  García Muñoz, Ricardo ^a   Feliu, Jesús ^b   Llorente, Luis ^c  

^a HOSPITAL SAN PEDRO   (Spain)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Anergy; Chronic lymphocytic leukemia; Germinal center exclusion; Immunological tolerance theory; Receptor edition; Stem cells

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE RECEPTOR;

ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CROSS LINKING; GERMINAL CENTER; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENESIS; PRE B LYMPHOCYTE; SOMATIC HYPERMUTATION; SURFACE PROPERTY; ANIMAL; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANIMALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84920279756     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.10.005     Document Type: Article

References (75)

1. Burnet M. Tolerance and paralysis. Sir Mackfarlane Burnet auto-immunity and auto-immune disease 1972, 59. The Garden City Press Limited, Letchworth UK. 1st ed.
2. Kikushige Y., Ishikawa F., Miyamoto T., Shima T., Urata S., Yoshimoto G., et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011, 20:246-259.
3. Hadzidimitriou A., Darzentas N., Murray F., Smilevska T., Arvaniti E., Tresoldi C., et al. Evidence for the significant fole of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood 2009, 113:403-411.
4. Coelho V., Krysov S., Steele A., Sanchez Hidalgo M., Johnson P.W., Chana P.S., et al. Identification in CLL of circulating intraclonal subgroups with varying B cell receptor expression and function. Blood 2013, 122:2664-2672.
5. Dühren-von Minden M., Übelhart R., Schneider D., Wossning T., Bach M.P., Buchner M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
6. Rassenti L.Z., Kipps T.J. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. JExp Med 1997, 185:1435-1445.
7. Croci D.O., Morande P.E., Dergan-Dylon S., Borge M., Toscano M.A., Stupirski J.C., et al. Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 2013, 27:1413-1416.
8. Meixlsperger S., Köhler F., Wossning T., Reppel M., Müschen M., Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 2007, 26:323-333.
9. Garcia-Muñoz R., Llorente L. Chronic lymphocytic leukemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?. Immunology 2014, 142:536-540.
10. Herman S.E., Mustafa R.Z., Gyamfi J.A., Pittaluga S., Chang S., Chang B., et al. Ibrutinib inhibits B cell receptor and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with chronic lymphocytic leukemia. Blood 2014, 123:3286-3295.
11. Hexner E.O., Emerson S.G. Stem cell biology. Hematopoietic stem cell transplantation 2008, 3. Humana Press, Totowa NJ USA. 2nd ed. R.J. Soiffer (Ed.).
12. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cáncer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
13. Bonet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
14. Nakajima P.B., Kieffer K., Price A., Bosma G.C., Bosma M.J. Two distinct populations of H chain edited B cells show differential surrogate L chain dependence. JImmunol 2009, 182:3583-3596.
15. Zhang M., Srivastava G., Lu L. The pre-B cell receptor and its function during B cell development. Cell Mol Immunol 2004, 1:89-94.
16. van Loo P.F., Dingjan G.M., Maas A., Hendriks R.W. Surrogate-light-chain silencing is not critical for the limitation of pre-b cell expansion but is for the rumination of constitutive signaling. Immunity 2007, 27:468-480.
17. Kuppers R., Klein U., Hansmann M.L., Rajewsky K. Cellular origin of human B cell lymphomas. NEngl J Med 1999, 341:1520-1529.
18. λ2-14 gene use and homologous CDR3s: implication recognition of a common antigen epitope. Blood 2003, 101:4952-4957.
19. Wardemann H., Hamersen J., Nussenszeig M.C. Human autoantibody silencing by immunoglobulin light chains. JExp Med 2004, 200:191-199.
20. Wang J.H., Alt F.W., Gostissa M., Datta A., Murphy M., Alimzhanov M.B., et al. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cellsthat have undergone editing and switching. JExp Med 2008, 205:3079-3090.
21. García-Muñoz R., Panizo C., Bendandi M., Llorente L. Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?. Leuk Res 2009, 33:1437-1439.
22. Yonetani N., Ueda C., Akasaka T., Nishikori M., Uchiyama T., Ohno H. Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion 5' region of BCL-2 in B cell tumors. Jpn J Cancer Res 2001, 92:933-940.
23. Kobrin C., Cha S.C., Qin H., Raffeld M., Fend F., Wuintanilla-Martinez L., et al. Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis. Leuk Lymphoma 2006, 47:1523-1534.
24. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. JExp Med 2005, 201:703-711.
25. Herve M., Xy K., Ys Ng, Wardemann H., Albesiano E., Messmer B.T., et al. Unmutated and mutated chronic lymphocytic leukemia derive from self-reactive B cell precursors despite expressing different antibody reactivity. JClin Invest 2005, 115:1636-1643.
26. Chu C.C., Catera R., Hatzi K., Yan X.J., Zhang L., Wang X.B., et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008, 112:5122-5129.
27. Catera R., Silverman G.J., Hatzi K., Seiler T., Didier S., Zhang L., et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008, 14:665-674.
28. Lanemo Myhrinder A., Hellqvist E., Sidorova E., Söderberg A., Baxendale H., Dahle C., et al. Anew perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008, 111:3838-3848.
29. Sthoeger Z.M., Wakai M., Tse D.B., Vinciguerra V.P., Allen S.L., Budman D.R., et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. JExp Med 1989, 169:255-268.
30. Primer on the rheumatic diseases 2001, Arthritis Foundation, Atlanta GA, USA. 12th ed. J.H. Klippel, L.J. Crofford, J.H. Stone, C.M. Weyland (Eds.).
31. Hoogeboom R., Wormhoudt T.A., Schipperus M.R., Langerak A.W., Dunn-Walters D.K., Guikema J.E., et al. Anovel chronic lymphocytic leukemia subset expressing mutated IGHV3-7 encoded rheumatoid factor B cell receptors that are functionally proficient. Leukemia 2013, 27:738-740.
32. Hoogeboom R., van Kessel K.P., Hochstenbach F., Wormhoudt T.A., Reinten R.J., Wagner K., et al. Amutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. JExp Med 2013, 210:59-70.
33. García-Muñoz R., Galiacho V.R., Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol 2012, 91:981-996.
34. Duty J.A., Sodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., et al. Functional anergy in a subpopulation of naive B cells from healthy human cells that express autoreactive immunoglobulin receptors. JExp Med 2009, 206:139-151.
35. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109:4424-4431.
36. Muzio M., Apollonio B., Scielzo C., Frenquelli M., Vandoni I., Boussiotis V., et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112:188-195.
37. Apollonio B., Scielzo C., Bertilaccio M.T., Ten Hacken E., Scarfò L., Ranghetti P., et al. Targeting B cell anergy in chronic lymphocytic leukemia. Blood 2013, 121:3879-3888.
38. Cappione A., Anolik J.H., Pugh-Bernard A., Barnard J., Dutcher P., Silverman G., et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. JClin Invest 2005, 115:3205-3216.
39. Pugh-Bernard A.E., Silverman G.J., Cappione A.J., Villano M.E., Ryan D.H., Insel R.A., et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. JClin Invest 2001, 108:1061-1070.
40. Matejuk A., Beardall M., Xy Y., Tian Q., Phillips D., Alabyev B., et al. Exclusion of natural autoantibody-producing B cells from IgG memory B cell compartment during T cell-dependent immune response. JImmunol 2009, 182:7634-7643.
41. + memory B cell development. JExp Med 2006, 203:393-400.
42. Murrray F., Darzentas N., Hadzidimitrioy A., Tobin G., Boudjogra M., Scielzo C., et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008, 111:1524-1533.
43. Kulis M., Heath S., Bibikova M., Queiros A.C., Navarro A., Clot G., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012, 44:1236-1242.
44. Papakonstantinou N., Ntoufa S., Chartomatsidou E., Papadopoulos G., Hatzigeorgiou A., Anagnostopoulos A., et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med 2013, 19:115-123.
45. Fulci V., Chiaretti S., Goldoni M., Azzalin G., Carucci N., Tavolaro S., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109:4944-4951.
46. Calin G.A., Liu C.G., Sevignani C., Ferracin M., Felli N., Dumitru C.D., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004, 101:11755-11760.
47. Puente X.S., Pinyol M., Quesada V., Conde L., Ordóñez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475(7354).
48. Rosati E., Sabatini R., Rampino G., Tabilio A., Di Ianni M., Fettucciari K., et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009, 113:856-865.
49. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. JExp Med 2011, 208:1389-1401.
50. Rossi D., Rasi S., Fabbri G., Spina V., Fangazio M., Forconi F., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012, 119:521-529.
51. Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, etal. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 201;44:47-52.
52. Wang L., Lawrence M.S., Wan Y., Stojanov P., Sougnez C., Stevenson K., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. NEngl J Med 2011, 365:2497-2506.
53. Balatti V., Bottoni A., Palamarchuk A., Alder H., Rassenti L.Z., Kipps T.J., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012, 119:329-331.
54. Balatti V., Lerner S., Rizzotto L., Rassenti L.Z., Bottoni A., Palamarchuk A., et al. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia 2013, 27:740-743.
55. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. NEngl J Med 2000, 343:1910-1916.
56. Cadera E.J., Wang F., Amin Rh, Nolla H., Lenardo M.J., Schlissel M.S. NF-kappaB activity marks cells engaged in receptor editing. JExp Med 2009, 206:1803-1816.
57. Chavez J.C., Sahakian E., Pinilla-Ibanz J. Ibrutinib: an evidence-based review of its potential in the treatment of advances chronic lymphocytic leukemia. Core Evid 2013, 8:37-45.
58. Kharfan-Dabaja M.A., Wierda W.G., Cooper L.J. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2014, 28:507-517.
59. Cheng S., Ma J., Guo A., Lu P., Leonard J.P., Coleman M., et al. BTK inhibition targets invivo CLL proliferation through its effects on B cell receptor signaling activity. Leukemia 2014, 28:649-657.
60. Herman S.E., Gordon A.L., Wagner A.J., Heerema N.A., Zhao W., Flynn J.M., et al. Phosphatidykinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116:2078-2088.
61. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic keukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
62. Brown J.R., Byrd J.C., Coutre S.E., Benson D.M., Flinn I.W., Wagner-Johnston N.D., et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014, 123:3390-3397.
63. Winker D.G., Faia K.L., DiNitto J.P., Ali J.A., White K.F., Brophy E.E., et al. PI3k-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013, 20:1364-1374.
64. Kardava L., Yang Q., st Leger A., Foon K.A., Lentzsch S., Vallejo A.N., et al. The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells. Int Immunol 2001, 23:375-384.
65. Quong M.W., Martensson A., Langerak A.W., Rivera R.R., Nemazee D., Murre C., et al. Receptor editing and marginal zone B cell development are regulated by the helix-loop-helix protein E2A. JExp Med 2004, 199:1101-1112.
66. Seifert M., Sellmann L., Biehdorn J., Wein F., Stilgenbauer S., Dürig J., et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. JExp Med 2012, 209:2183-2198.
67. Opezzo P., Dumas G., Lalane A.I., Payelle-Brogard B., Magnac C., Pritsch O., et al. Different isoforms of BASAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. Blood 2005, 105:2495-2503.
68. Gutierrez A., Tscumper R.C., Wu X., Shanafelt T.D., Eckel-Passow J., Huddleston P.M., et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B cell lymphocytosis. Blood 2010, 116:2975-2983.
69. Gutierrez A., Arendt B.K., Tschumper R.C., Kay N.N.E., Zent C.S., Jelinek D.F. Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression. Plos One 2011, 6. e26056.
70. Nganga V.K., Palmer V.L., Naushad H., Kassmeier M.D., Anderson D.K., Perry G.A., et al. Accelerated progression of chronic lymphocytic leukemia in Εμ-TCL-1 mice expressing catalytically inactive RAG1. Blood 2013, 121:3855-3866.
71. Havelange V., Pekarsky Y., Nakamura T., Palamarchuk A., Alder H., Rassenti L., et al. IRF-4 mutations in chronic lymphocytic leukemia. Blood 2011, 118:2827-2829.
72. Chang C.C., Lorek J., Sabath D.E., Li Y., Chitambar C.R., Logan B., et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B cell chronic lymphocytic leukemia. Blood 2002, 100:4671-4675.
73. Duckworth A., Glenn M., Slupsky J.R., Packham G., Kalakonda N. Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. Blood 2014, 123:3277-3285.
74. Gilling C.E., Mittal A.K., Chaturvedi N.K., Iqbal J., Aoun P., Bierman P.J., et al. Lymph node-induced immune tolerance in chronic lymphocytic leukaemmia: a role of caveolin-1. Br J Haematol 2012, 158:216-231.
75. Cutucache C.E. Tumor-induced host immunosuppression: special focus on CLL. Int Immunopharmacol 2013, 17:35-41.